Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 59 |
| Active Pipeline (Recruiting Now) | 25 (16) |
| Completed vs Stopped Early | 27 / 6 (10.2%) |
| Median Closed Actual Enrollment | 183 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Beijing Cancer Hospital | Beijing, Beijing Municipality | 11 |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang | 9 |
| The Affiliated Hospital of Qingdao University | Qingdao, Shandong | 8 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06954467 | JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma | Phase II | RECRUITING |
| NCT07876557 | A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative | Phase II | RECRUITING |
| NCT06095583 | Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lu | Phase III | RECRUITING |
| NCT07284134 | JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. | Phase III | RECRUITING |
| NCT07045311 | JS207 Combination Therapy in Triple-negative Breast Cancer | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Shanghai Junshi Bioscience Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.